Table 3.

Effectiveness and costs by treatment group

Characteristic	Paricalcitol	Cinacalcet	p valuea
Subjects [n]	51	47
Effectiveness [n (%)]
Primary endpoint
iPTH level 150–300 pg/mLb	29 (56.9)	16 (34.0)	0.0235
Secondary endpoints
≥30 % reduction in iPTH levelc	43 (84.3)	23 (48.9)	0.0002
≥50 % reduction in iPTH leveld	33 (64.7)	10 (21.3)	<0.0001
Calcium level 8.4–10.5 mg/dLe	47 (92.2)	25 (53.2)	<0.0001
iPTH level 150–300 pg/mL and calcium level 8.4–10.5 mg/dLf	27 (52.9)	8 (17.0)	0.0002
Costs [US$; mean ± SD]g
Cost of study drugs	2,979 ± 2,422	9,264 ± 7,275	<0.0001
Cost of phosphate binders	7,173 ± 6,987	6,703 ± 8,380	0.7645
Total drug cost	10,153 ± 7,751	15,967 ± 11,734	0.0053

iPTH intact parathyroid hormone, SD standard deviation

^aDifferences between groups were considered statistically significant (indicated by bold text) if p < 0.05 on the basis of Pearson’s chi-squared test or Student’s t test

^bProportion of subjects achieving a mean iPTH level of 150–300 pg/mL during the evaluation period (weeks 21–28)

^cProportion of subjects achieving ≥30 % reduction in the mean iPTH level during the evaluation period compared with baseline

^dProportion of subjects achieving ≥50 % reduction in the mean iPTH level during the evaluation period compared with baseline

^eProportion of subjects with a mean calcium level of 8.4–10.5 mg/dL during the evaluation period

^fProportion of subjects achieving both a mean iPTH level of 150–300 pg/mL and a mean calcium level of 8.4–10.5 mg/dL during the evaluation period

^gCosts were annualized on the basis of dosages in the evaluation period